Originally published Jan. 16.
In a pharmacogenetic investigation conducted by researchers in the Netherlands, Bayer's Nexavar was not able to improve survival in patients with KRAS-mutated non-small cell lung cancer.
The headline and this story have been updated to reflect that BMS and Lilly have submitted to the FDA retrospective analysis on Erbitux's efficacy in colorectal cancer patients with wild-type KRAS mutations, which the agency may use to update the drug label.
Anagnostics said this week that it has tapped fellow Austrian firm Vela Laboratories to be its first service partner. Vienna-based Vela will now offer its pharmaceutical and biotech clients the ability to use Anagnostics' cylindrical HybCell microarray platform.
Express Scripts is the only one out of the big three PBMs that hasn't yet made an acquisition to directly support a personalized medicine focus. However, the firm has expressed an interest in applying PGx strategies to rein in healthcare costs, and acquiring Medco would bring it such capabilities.
Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.
An expanded license with Dana-Farber Cancer Institute for an offshoot of its Cold-PCR technology allows Transgenomic to develop kits that can detect mutations in common cancer-related genes such as KRAS and P53 directly from blood samples and then analyze the variants using multiple sequencing approaches.